Kennedy Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Kennedy Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-5,106	Closed	-$2.68M	–	601
2025 Q2	$2.68M	Buy	5,106 +90	+2%	+$50.2K	0.06%	396
2025 Q1	$3.18M	Sell	5,016 -140	-3%	-$96.3K	0.08%	361
2024 Q4	$3.67M	Buy	5,156 +652	+14%	+$547K	0.08%	383
2024 Q3	$4.73M	Sell	4,504 -3,581	-44%	-$3.99M	0.1%	330
2024 Q2	$8.5M	Buy	8,085 +2,672	+49%	+$2.59M	0.18%	189
2024 Q1	$5.21M	Buy	+5,413	New	+$5.15M	0.11%	314

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Kennedy Capital Management's REGN Position: Q3 2025 in Review

Kennedy Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 5,106 shares — an estimated $2.68M sold.

Kennedy Capital Management first reported a position in REGN in Q1 2024 and held it in 6 quarters. The position peaked at $8.5M in Q2 2024. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

Kennedy Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Kennedy Capital Management sold 5,106 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $2.68M.
Kennedy Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2024 and held it in 6 quarters.
Kennedy Capital Management's Regeneron Pharmaceuticals position peaked at $8.5M in Q2 2024.
1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Kennedy Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.